Investigational drug · Phase 3
CC-99282
Also called: BMS-986369, Golcadomide
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
23
Any phase or sponsor naming "CC-99282"
First trial start
2019
May 20, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CC-99282", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lymphoma, Follicular
- Large B-cell Lymphoma
- Non-Hodgkin Lymphoma
- Relapsed/Refractory Non-Hodgkin Lymphoma
- Lymphoma, Non-Hodgkin
- Follicular Lymphoma
- Relapsed or Refractory T-cell Lymphomas
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "CC-99282" as an intervention, largest first.
- Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell LymphomaPivotal-lookingActive, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT06356129 · 850 participants (planned) · Start Jun 19, 2024 · Primary completion Aug 9, 2027
Drug: Golcadomide; Placebo and 5 more · For: Large B-cell Lymphoma
Sites: Mobile, Alabama; Anchorage, Alaska; Phoenix, Arizona · 325 sites in all
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06090539 · 460 participants (planned) · Start Dec 29, 2023 · Primary completion Oct 28, 2027
Drug: BMS-986458; Rituximab and 4 more · For: Relapsed/Refractory Non-Hodgkin Lymphoma
Sites: Phoenix, Arizona; Duarte, California; Jacksonville, Florida · 76 sites in all
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Active, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT03930953 · 438 participants (planned) · Start May 20, 2019 · Primary completion Apr 7, 2027
Drug: CC-99282; Rituximab and 3 more · For: Lymphoma, Non-Hodgkin
Sites: Scottsdale, Arizona; Jacksonville, Florida; Tampa, Florida · 66 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT06911502 · 400 participants (planned) · Start Jul 28, 2025 · Primary completion Apr 24, 2028
Drug: Golcadomide; Rituximab and 6 more · For: Follicular Lymphoma
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 160 sites in all
GenmabIndustry
NCT05283720 · 264 participants · Start Jun 14, 2022 · Primary completion Nov 2032
Drug: Epcoritamab; Lenalidomide and 7 more · For: Non-Hodgkin Lymphoma
Sites: Tucson, Arizona; New Haven, Connecticut; Newark, Delaware · 76 sites in all
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaActive, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT04884035 · 224 participants (planned) · Start Sep 15, 2021 · Primary completion Dec 1, 2028
Drug: CC-220; Rituximab and 7 more · For: Lymphoma, B-Cell
Sites: Birmingham, Alabama; Scottsdale, Arizona; Duarte, California · 36 sites in all
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05169515 · 121 participants (planned) · Start Oct 26, 2022 · Primary completion Apr 30, 2029
Drug: SC Mosunetuzumab; IV Glofitamab and 4 more · For: Non-Hodgkin Lymphoma
Sites: San Francisco, California; Aurora, Colorado; Tampa, Florida · 24 sites in all
- A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaActive, not recruiting
CelgeneBristol Myers Squibb (BMY)
NCT06425302 · 95 participants · Start Aug 30, 2024 · Primary completion Jun 19, 2026
Drug: Golcadomide; Rituximab and 5 more · For: Lymphoma, Follicular
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 56 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06108232 · 83 participants (planned) · Start Mar 15, 2024 · Primary completion Dec 31, 2027
Drug: Obinutuzumab; CC-99282 · For: Follicular Lymphoma; Tumor
Sites: Houston, Texas
- A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Active, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06035497 · 83 participants (planned) · Start Nov 20, 2023 · Primary completion Aug 11, 2026
Drug: BMS-986369 · For: Relapsed or Refractory T-cell Lymphomas
Sites: Anjo-shi, Japan; Nagoya, Japan; Toyohashi, Japan · 40 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Model-informed optimal dose selection of golcadomide in combination with R-CHOP in patients with previously untreated aggressive B-cell lymphoma.
Zheng X, Yu Z, Kaplan M, et al. · Br J Clin Pharmacol 2026
- Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma.
Miyazaki K · Int J Clin Oncol 2026
- Diffuse Large B-Cell Lymphoma Presenting in a Background of Rosai-Dorfman Disease.
Wu C, Meyer A, Tun AM · Case Rep Hematol 2026
- Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma.
Mo Z, Groocock L, Wood S, et al. · Blood Cancer Discov 2026
- Novel Cereblon-Binding Immunomodulators Have Increased Potency Against Gammaherpesvirus- Associated Lymphomas In Vitro.
Shrestha P, Treco EN, Davis DA, et al. · J Med Virol 2025
- Leveraging efficiency metrics for the optimization of CELMoDsࡊ as cereblon-based molecular glue degraders.
Jia L, Riggs JR, Weiss DR, et al. · RSC Med Chem 2025
Also in development for Lymphoma, Follicular
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- AbexinostatPCI-24781Phase 35 trials
Xynomic Pharmaceuticals, Inc. · Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.